Senior finance executive focused on corporate strategy, M&A and capital markets, with experience advising PE sponsors and corporates on transactions, restructuring and liquidity management. Roseann Higgins combines operational finance leadership with investor relations oversight, supporting due diligence, earnings communications and post-deal integration. Market-relevant strengths include financial modelling, stakeholder engagement and cross-border deal execution.
Senior finance executive focused on corporate strategy, M&A and capital markets, with experience advising PE sponsors and corporates on transactions, restructuring and liquidity management. Roseann Higgins combines operational finance leadership with investor relations oversight, supporting due diligence, earnings communications and post-deal integration. Market-relevant strengths include financial modelling, stakeholder engagement and cross-border deal execution.
Brings a transaction-focused, value-oriented investment approach centered on disciplined capital allocation, rigorous due diligence and active portfolio stewardship. Prefers opportunities where strategic M&A, capital-structure optimization and operational integration can unlock value; emphasizes liquidity management, scenario modeling and clear exit pathways. Uses a cross-border, sector-agnostic lens with preference for companies where finance leadership and governance improvements accelerate returns. Time horizon is medium-to-long, with risk managed through covenant, downside protection and staged capital deployment.
Brings a transaction-focused, value-oriented investment approach centered on disciplined capital allocation, rigorous due diligence and active portfolio stewardship. Prefers opportunities where strategic M&A, capital-structure optimization and operational integration can unlock value; emphasizes liquidity management, scenario modeling and clear exit pathways. Uses a cross-border, sector-agnostic lens with preference for companies where finance leadership and governance improvements accelerate returns. Time horizon is medium-to-long, with risk managed through covenant, downside protection and staged capital deployment.
| Trades 1407 | Longs Won 904/1407 64% | Profit Factor 4.67 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $561,676.99 |
| Average Win $196,299.3 | Best Trade (Aug 14) $9.81M | Sharpe Ratio -218.98 |
| Average Loss -$75,478.13 | Worst Trade (Sep 30) -$2.02M | Z-Score 3.49 (99.95%) |
| Commissions $0 | Avg. Trade Length 10m 3d | Expectancy $99,139.35 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 11,494 | 10,345 | 9,195 | 8,046 | 6,897 | 5,747 | 4,598 | 3,448 | 2,299 | 1,149 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 121,028 | $30.32M | $37.64M | - | $7.32M | 24.15% | +0.524% |
ABBV AbbVie Inc. | 15,689 | $2.79M | $3.82M | - | $1.04M | 37.2% | 0.0 |
ABT Abbott Laboratories | 44,447 | $4.96M | $4.69M | - | -$276,738.6 | -5.57% | 0.0 |
ACN Accenture plc Class A | 17,889 | $4.84M | $3.05M | - | -$1.79M | -36.91% | +0.176% |
ADI Analog Devices, Inc. | 35,538 | $7.86M | $13.51M | - | $5.65M | 71.93% | 0.0 |
ADP Automatic Data Processing Inc. | 18,156 | $5.11M | $4.86M | - | -$244,497.91 | -4.79% | -0.99% |
AFL Aflac Inc. | 31,476 | $3.26M | $3.95M | - | $689,009.84 | 21.12% | +0.328% |
AGG iShares Core U.S. Aggregate Bond ETF | 2,889 | $281,150.51 | $281,894.17 | - | $743.66 | 0.26% | -0.087% |
AMAT Applied Materials, Inc. | 292 | $211,116 | $161,198.6 | - | -$49,917.4 | -23.64% | +0.993% |
AMGN Amgen Inc. | 14,946 | $4.04M | $5.83M | - | $1.79M | 44.2% | 0.0 |
AMT American Tower Corporation | 10,011 | $1.91M | $1.68M | - | -$227,238.38 | -11.9% | -4.097% |
AMZN Amazon.com Inc | 33,358 | $7.32M | $9.25M | - | $1.93M | 26.35% | 0.0 |
APD Air Products and Chemicals, Inc. | 1,034 | $299,613.69 | $304,730.13 | - | $5,116.44 | 1.71% | 0.0 |
APH Amphenol Corporation | 40,944 | $1.41M | $3.51M | - | $2.09M | 148.08% | 0.0 |
AROW Arrow Financial Corporation | 6,000 | $172,260 | $239,040 | - | $66,780 | 38.77% | -2.329% |
AVGO Broadcom Inc. | 41,722 | $9.51M | $17.45M | - | $7.94M | 83.5% | 0.0 |
AXP American Express Company | 22,288 | $7.42M | $7.73M | - | $305,031.95 | 4.11% | 0.0 |
AZN AstraZeneca PLC American Depositary Shares | 20,406 | $4.01M | $3.3M | - | -$718,254.64 | -17.89% | +3.778% |
BAC Bank of America Corporation | 35,491 | $1.73M | $2.24M | - | $514,619.5 | 29.74% | +0.556% |
BCS Barclays PLC Sponsored ADR | 165,211 | $2.72M | $4.7M | - | $1.98M | 72.58% | +1.57% |